Document is current

Any future updates will be listed below

TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib

Crossref DOI link: https://doi.org/10.1007/s00259-016-3433-2

Published Online: 2016-06-03

Published Print: 2016-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark